Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 1–60 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…n. It is noticed that two patients switched from ocrelizumab to ofatumumab: one due to infusion-related adverse effects and another for lo…
…sient focal deficits and seizures to toxic leukoencephalopathy. Dextromethorphan (DXM), an N-methyl-D-aspartate (NMDA)-receptor antagonist, is used du…
…to pruritus and sleep outcomes compared with those treated with tralokinumab.Conflict of Interest No conflict of interest…
… treat endogenous Cushing’s syndrome, drugs such as metyrapone, ketoconazole, and osilodrostat are available to control hypercortisolism. In…
… two JAKi, and another 7% have received three. Drugs used were: upadacitinib (40%), baricitinib (35%), tofacitinib (24%), and filgotinib (11…
…ilisin/kexin type 9 inhibitors (PCSK9i), such as alirocumab and evolocumab, effectively manage cLDL levels. However, the relative efficacy…
…f care (26.3%). 31.5% of patients required a dose adjustment of binimetinib, and 21% discontinued treatment, with only one discontinuation …
…4 were 51.5% and 45.8% for ustekinumab, and 58.7% and 55.4% for vedolizumab, respectively. In Crohn’s disease, prior infliximab use, male s…
…nterventions to modify MMPs during DKA, for example, the use of minocycline, which is a potent inhibitor of MMP-9, may represent important …
…ssess safety and immunogenicity. Participants received vaccine (6MHP+mBRAF+poly-ICLC) with a dose-escalation allocation of CDX-1140 …
…ater cumulative time in LLDAS over 12 months is achieved in the rituximab group compared with placebo. We will also evaluate secondary ou…